Feedback Share Discussion Threads

[lr2] 16/11/2022 09:54

It's all gibberish to me but somebody out there is looking for the share price to bounce.

ADVFN won't let me print the link to the page so I've posted the relevant gibberish instead.

FDBK closed down 1.08 percent on Tuesday, November 15, 2022, on 0 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

[petekand] 16/11/2022 09:50

It’s not just India, most of the world does not support the view of the West towards Russia.

[ged5] 16/11/2022 09:45

India didn't take part in the sanctions against Russia.

Your second paragraph made me think that's how other countries view the UK!

FDBK is certainly testing our patience.

[yump] 16/11/2022 09:14

India also sits on the fence re Ukraine - presumably they’re dependent on Russia for something. Although of course much of Europe is/was as well and yet the latter are very clear about their position.

Thanks to Brexit we have to look for trade to some of the countries that are less desireable to deal with - dodgy corruption - exploitation of their people for low wages etc

[chopper harris1] 15/11/2022 16:25

What the hell wwre they thinking of with the 200:1 consolidation?

10:1?, yes, possibly, if they wanted to make some kind of statement which might have taken the FDBK share price a little out of typical penny share territory in the eyes of some. But 200:1? Sheer bloody madness which has almost certainly given most of us very little chance of ever getting our money back.
Which clowns gave our hapless FDBK chumps this advice?

[chopper harris1] 15/11/2022 16:13

This Oakley geezer needs to be made to understand that he is living on borrowed time unless he brings some SIGNIFICANT positive development to the company’s revenue stream in the near future.

If he thinks that he can just swan through the next couple of years producing what he’s produced for the last couple, then he has another think coming.

[lr2] 15/11/2022 13:56

First class flim-flam wasn't it Duc? Christ, we need some positive news to get people buying around here. Like watching paint dry at present.

[ducatiman] 15/11/2022 13:46

The Directors' consider that the Share Consolidation will result in a more appropriate share capital structure for the Company which is expected to:

-- increase the Company's share price proportionately which may consequently positively impact the liquidity of and trading activity in the Company's shares;


The shareholders consider that the directors were wrong.
The shareholders wonder when the directors will be compelled to buy some shares to take advantage of their error?

[yump] 14/11/2022 16:53

Nice. Our NHS in bed with some more psychopathic megalomaniacs, helped by the most slippery adviser we've had in government.

I think a system to store all patient data is a separate entity to a pathway management system.

[petekand] 14/11/2022 16:26

Okay thanks. Tom boy will probably volunteer to collect it for them and hand it on a silver plate for free via carelocker.
Not quite sure but it does sound awfully similar to the model here, ie. the patient centric journey which brings me back to my original question.
There is just simply no clarity here whilst the company operate in near radio silence, treating holders like mushrooms.

[ged5] 14/11/2022 10:35

I'm not sure it affects Bleepa or even Carelocker.

I posted about Palantir on another thread back in 2020. Cummings brought Ben Warner onto SAGE and used the pandemic to collect our data. That's all they are interested in. They want the data but will allow others to collect it for them so Carelocker is ideal for them.

No problem for FDBK imo but there is legislation which will allow our data to be collected and put in the hands of foreign companies.

[petekand] 13/11/2022 15:31

How does this leave Bleepa/Carelocker if the NHS is looking to roll this out.
During the last interview after the £500k pilot extension, Tom boy did not seem too certain about anything after March, only hoping to be part of the procurement process.

[lr2] 12/11/2022 12:19

The following is courtesy of Vascular over on the other place.
A very good update on the progress so far at Royal Berkshire.
_____________________________________________________________

This was posted by FDBK yesterday on various social media. Its a highly positive piece regarding progress at the Royal Berkshire.

[yump] 11/11/2022 16:49

In the end I think this just falls into yet another product that appears to be exciting, but has the same problem as every new thing sold into the NHS - it just takes years and years.

I thought the theoretical benefit of Bleepa was that it wasn't a medical product and therefore might have a chance of leapfrogging some of the hoops that medical products have to go through.

More fool me. The biggest hoop, regardless of what the product is, is getting any sort of overall or majority use in a trust that is a requirement to use, not some sort of use based on all the individual whims of clinical teams.

That hoop is there for non-clinical products as well.

My wife used to come back frustrated beyond belief, from clinical meetings where the 'top' clinician always ran the meeting and basically talked all the way through the agenda, telling people what to do. No input or debate.

She once said that if a manager came in with the most comfortable chairs in the world for everyone, the team would never agree to use them - because it was the manager who suggested them.

I once asked who they were all answerable to and she asked what I meant, they were a joint team. The idea of being answerable for anything, even non-clinical, to someone independent was a no-no, even if the team was massively disfunctional, which it was.

[pugugly] 11/11/2022 10:49

yump - Agreed got to try varied approaches to get sales BUT nothing usually beats a detailed cost benefit analysis of the product/service you are offering - in whatever field.

Message received after following for a long time is that either the product cannot show significant superiority (for whatever reason) or that management/sales are unable to capitalize on the benefits. I strongly suspect a mixture of both.

Left field possibility? Could the coming strikes in the NHS offer a break-through opportunity or the final nail in the coffin?

[lr2] 10/11/2022 13:10

Not working so far, is it? They could try releasing some positive news, perhaps.

[ducatiman] 10/11/2022 12:26

The Directors' consider that the Share Consolidation will result in a more appropriate share capital structure for the Company which is expected to:

-- increase the Company's share price proportionately which may consequently positively impact the liquidity of and trading activity in the Company's shares;

[lr2] 07/11/2022 23:55

Courtesy of Vascular over on the other site.

56 Accelerator alumni feature in Department of International Trade 2023 Digital Health Playbook

Posted on November 2, 2022 by DigitalHealth.London

[yump] 07/11/2022 23:46

Forgot I'd got some FDBK shares for a while - are we rich yet ?